Effect of Mesenchymal Stem Cells on Doxorubicin-induced Fibrosis

Overview

Journal Cell J

Specialty Cell Biology

Date 2013 Mar 20

PMID 23508361

Citations 18

Authors

Simin Mohammadi Gorji

Abbas Ali Karimpor Malekshah

Mohammad Baghere Hashemi-Soteh

Alireza Rafiei

Kazem Parivar

Nasser Aghdami

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to test the effect of intravenous injection of mesenchymal stem cells (MSCs) on doxorubicin (DOX)-induced fibrosis in the heart. We investigated the mechanisms that possibly mediate this effect.

Materials And Methods: In this experimental study, fibrosis in the myocardium of adult male Wistar rats (weights 180-200 g, 9-10 weeks of age, total n=30) was created by DOX administration. DOX (2.5 mg/kg) was administered intraperitoneally 3 times a week, for a total dose of 15 mg/kg over a period of 2 weeks. MSCs from Wistar rats were separated and cultured in Dulbecco's modified eagle medium (DMEM). The condition medium (CM) which contained factors secreted by MSCs was also collected from MSCs cultured in serum-free DMEM. Two weeks after the first injection of DOX, MSCs, CM and standard medium (SM) were transplanted via intravenous injection. Four weeks after transplantation, histological (Masson's trichrome staining for fibrosis detection) and molecular [real-time polymerase chain reaction (RT-PCR)] analyses were conducted. In addition, insulin-like growth factor (IGF-1) and hepatocyte growth factor (HGF) in the CM were measured with an enzyme-linked immunosorbent assay (ELISA). For immunosuppressive treatment, cyclosporine A was given (intraperitoneally, 5 mg/kg/day) starting on the day of surgery until the end of study in all groups. Fibrosis rate and relative gene expression were compared by analysis of variance (ANOVA) and post-Tukey's test. HGF and (IGF-1 in the CM were analyzed by independent sample t test. P<0.01 was considered statistically significant.

Results: Our data demonstrated that intravenously transplanted MSCs and CM significantly reduced fibrosis and significantly increased Bcl-2 expression levels in the myocardium compared to the DOX group (p<0.01). However, there was no significant difference between Bax expression levels in these groups. In addition, secretion of HGF and IGF-1 was detected in the CM (p<0.01).

Conclusion: We conclude that intravenous transplantation of MSCs and CM can attenuate myocardial fibrosis and increase Bcl-2 expression. This may be mediated by paracrine signaling from MSCs via anti-fibrotic and anti-apoptotic factors such as HGF and IGF-1.

Citing Articles

Mesenchymal Stem Cells in Myelodysplastic Syndromes and Leukaemia.

Eroz I, Kakkar P, Lazar R, El-Jawhari J Biomedicines. 2024; 12(8).

PMID: 39200142 PMC: 11351218. DOI: 10.3390/biomedicines12081677.

The Role of Mesenchymal Stem Cells and Imatinib in the Process of Liver Fibrosis Healing Through and Axes.

Varjavand P, Hesampour A Rep Biochem Mol Biol. 2024; 12(2):350-358.

PMID: 38317807 PMC: 10838597. DOI: 10.61186/rbmb.12.2.350.

Breast milk mesenchymal stem cells abate cisplatin-induced cardiotoxicity in adult male albino rats via modulating the AMPK pathway.

Nageeb M, Saadawy S, Attia S Sci Rep. 2022; 12(1):17554.

PMID: 36266413 PMC: 9585145. DOI: 10.1038/s41598-022-22095-2.

Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury: Insights Into the SENECA Trial.

OBrien C, Ozen M, Ikeda G, Vaskova E, Jung J, Bayardo N JACC CardioOncol. 2021; 3(3):428-440.

PMID: 34604804 PMC: 8463733. DOI: 10.1016/j.jaccao.2021.05.006.

The emerging therapeutic role of mesenchymal stem cells in anthracycline-induced cardiotoxicity.

Lan H, Xue Q, Liu Y, Jin K, Fang X, Shao H Cell Tissue Res. 2021; 384(1):1-12.

PMID: 33433685 DOI: 10.1007/s00441-020-03364-w.

References

He A, Jiang Y, Gui C, Sun Y, Li J, Wang J . The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning. Can J Cardiol. 2009; 25(6):353-8. PMC: 2722478. DOI: 10.1016/s0828-282x(09)70094-7. View

Sabbah H . Apoptotic cell death in heart failure. Cardiovasc Res. 2000; 45(3):704-12. DOI: 10.1016/s0008-6363(99)00348-x. View

Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M . Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol. 2004; 287(6):H2670-6. DOI: 10.1152/ajpheart.01071.2003. View

Cselenyak A, Pankotai E, Horvath E, Kiss L, Lacza Z . Mesenchymal stem cells rescue cardiomyoblasts from cell death in an in vitro ischemia model via direct cell-to-cell connections. BMC Cell Biol. 2010; 11:29. PMC: 2869333. DOI: 10.1186/1471-2121-11-29. View

Xu R, Chen X, Chen J, Han Y, Han B . Mesenchymal stem cells promote cardiomyocyte hypertrophy in vitro through hypoxia-induced paracrine mechanisms. Clin Exp Pharmacol Physiol. 2008; 36(2):176-80. DOI: 10.1111/j.1440-1681.2008.05041.x. View

Ferreira A, Matsubara L, Matsubara B . Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem. 2008; 6(4):278-81. DOI: 10.2174/187152508785909474. View

Oltvai Z, Milliman C, Korsmeyer S . Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993; 74(4):609-19. DOI: 10.1016/0092-8674(93)90509-o. View

Choi E, Lee N, Kim H, Kim M, Chi S, Kwon D . Schisandra fructus extract ameliorates doxorubicin-induce cytotoxicity in cardiomyocytes: altered gene expression for detoxification enzymes. Genes Nutr. 2008; 2(4):337-45. PMC: 2478487. DOI: 10.1007/s12263-007-0073-y. View

Hill M, Chow D, Singal P . Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation. 1995; 91(1):10-5. DOI: 10.1161/01.cir.91.1.10. View

10.

Collins J, Russell B . Stem cell therapy for cardiac repair. J Cardiovasc Nurs. 2009; 24(2):93-7. PMC: 2700234. DOI: 10.1097/JCN.0b013e318197a7db. View

11.

Ma J, Ge J, Zhang S, Sun A, Shen J, Chen L . Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol. 2005; 100(3):217-23. DOI: 10.1007/s00395-005-0521-z. View

12.

Nicholson D, Thornberry N . Apoptosis. Life and death decisions. Science. 2003; 299(5604):214-5. DOI: 10.1126/science.1081274. View

13.

Kaul N, Singal P . Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation. 1994; 89(6):2829-35. DOI: 10.1161/01.cir.89.6.2829. View

14.

Frias M, Lang U, Gerber-Wicht C, James R . Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc Res. 2009; 85(1):118-26. DOI: 10.1093/cvr/cvp289. View

15.

Lai R, Arslan F, Lee M, Sze N, Choo A, Chen T . Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010; 4(3):214-22. DOI: 10.1016/j.scr.2009.12.003. View

16.

Schuleri K, Feigenbaum G, Centola M, Weiss E, Zimmet J, Turney J . Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J. 2009; 30(22):2722-32. PMC: 2777027. DOI: 10.1093/eurheartj/ehp265. View

17.

Chen X, Chen Y, Bi Y, Fu N, Shan C, Wang S . Preventive cardioprotection of erythropoietin against doxorubicin-induced cardiomyopathy. Cardiovasc Drugs Ther. 2007; 21(5):367-74. DOI: 10.1007/s10557-007-6052-0. View

18.

Guo K, Schafer R, Paul A, Gerber A, Ziemer G, Wendel H . A new technique for the isolation and surface immobilization of mesenchymal stem cells from whole bone marrow using high-specific DNA aptamers. Stem Cells. 2006; 24(10):2220-31. DOI: 10.1634/stemcells.2006-0015. View

19.

Park K, Kim S, Gul R, Kim B, Jang K, Chung H . Fatty acids ameliorate doxorubicin-induced intracellular ca2+ increase and apoptosis in rat cardiomyocytes. Biol Pharm Bull. 2008; 31(5):809-15. DOI: 10.1248/bpb.31.809. View

20.

Mizuno S, Matsumoto K, Sawa Y, Matsuda H, Nakamura T . Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest. 2000; 106(12):1511-9. PMC: 387252. DOI: 10.1172/JCI10226. View